Displaying all 4 publications

Abstract:
Sort:
  1. Sharan J, Chanu NI, Jena AK, Arunachalam S, Choudhary PK
    J Indian Orthod Soc, 2020 Oct;54(4):352-365.
    PMID: 34191889 DOI: 10.1177/0301574220964634
    OBJECTIVES: To provide comprehensive information regarding the implications of the coronavirus disease 2019 (COVID-19), mode of transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and its effects on orthodontic care during the pandemic and post-pandemic outbreak of the disease, based on currently available literature and information.

    MATERIALS AND METHODS: A comprehensive research for studies that focused on the COVID-19 pandemic and orthodontic care up to August 18, 2020, with no language restriction. The databases included PubMed, MEDLINE, Scopus, Google Scholar, and COVID-19 Open Research Dataset (CORD-19) 2020. The research was focused on presenting symptoms, disease transmission, infection control, orthodontic care, and financial implications affecting the delivery of orthodontic treatment. The research also included reports from major health policy regulatory bodies such as World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Control and Prevention, and major international dental and orthodontic societies and associations. The peer-reviewed publications and guidelines from the health regulatory authorities were given priority.

    RESULTS: The latest information on the SARS-CoV-2 virus effects and orthodontic implications were arranged sequentially. The SARS-CoV-2 virus mode of transmission and its prevention were emphasized to keep the orthodontic and dental operatory safe for continuing practice.

    CONCLUSION: The COVID-19 outbreak has changed the way orthodontics is practiced. Strict infection control, near-zero aerosol production, and minimal touch dentistry are the keys to prevent contamination of orthodontic operatory. During the pandemic, only emergency orthodontic procedures could be extended to the orthodontic patient while adhering to all the regulatory guidelines. Fortunately, to date, there is no reported case of cross-transmission of the SARS-CoV-2 virus at the dental setup.

  2. Sharan J, Bajoria A, Jena AK, Sinha P, Shivakumar A, Kamal VK, et al.
    Turk J Orthod, 2024 Jun 30;37(2):104-111.
    PMID: 38952284 DOI: 10.4274/TurkJOrthod.2023.2023.14
    OBJECTIVE: To evaluate the infrazygomatic crest (IZC) bone and develop guidelines for the optimum placement of orthodontic miniscrew implants (OMSIs) along the distobuccal root of the permanent maxillary first molar.

    METHODS: Bone thickness of the IZC region of 50 young adults (25 males and 25 females) aged 18-30 years were evaluated using cone-beam computed tomography images. The infrazygomatic bone thickness along the distobuccal root of the permanent maxillary first molar was assessed at various insertion angles (40° to 75° i.r.t the maxillary occlusal plane) with an increment of 5°. Student's t-test was used to compare the IZC bone thickness and height at the orthodontic miniscrew insertion site for males and females on the right and left sides.

    RESULTS: The bone thickness of the IZC region above the distobuccal root of the permanent maxillary first molar was estimated between 4.39±0.25 mm and 9.03±0.45 mm for insertion angles from 40° to 75° to the maxillary occlusal plane. The corresponding OMSI insertion heights were 17.71±0.61 mm to 13.69±0.75 mm, respectively, above the maxillary occlusal plane. There were statistically significant gender and side-wise variations in bone thickness at the IZC area and insertion height.

    CONCLUSION: The safe position for OMSI placement at the IZC was 13.69-16 mm from the maxillary occlusal plane with an insertion angle between 55° and 75°. These parameters provide the optimum placement of OMSIs along the distobuccal root of the permanent maxillary first molar.

  3. Sahoo A, Fuloria S, Swain SS, Panda SK, Sekar M, Subramaniyan V, et al.
    Biomedicines, 2021 Oct 20;9(11).
    PMID: 34829734 DOI: 10.3390/biomedicines9111505
    In an emergency, drug repurposing is the best alternative option against newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. However, several bioactive natural products have shown potential against SARS-CoV-2 in recent studies. The present study selected sixty-eight broad-spectrum antiviral marine terpenoids and performed molecular docking against two novel SARS-CoV-2 enzymes (main protease or Mpro or 3CLpro) and RNA-dependent RNA polymerase (RdRp). In addition, the present study analysed the physiochemical-toxicity-pharmacokinetic profile, structural activity relationship, and phylogenetic tree with various computational tools to select the 'lead' candidate. The genomic diversity study with multiple sequence analyses and phylogenetic tree confirmed that the newly emerged SARS-CoV-2 strain was up to 96% structurally similar to existing CoV-strains. Furthermore, the anti-SARS-CoV-2 potency based on a protein-ligand docking score (kcal/mol) exposed that the marine terpenoid brevione F (-8.4) and stachyflin (-8.4) exhibited similar activity with the reference antiviral drugs lopinavir (-8.4) and darunavir (-7.5) against the target SARS-CoV-Mpro. Similarly, marine terpenoids such as xiamycin (-9.3), thyrsiferol (-9.2), liouvilloside B (-8.9), liouvilloside A (-8.8), and stachyflin (-8.7) exhibited comparatively higher docking scores than the referral drug remdesivir (-7.4), and favipiravir (-5.7) against the target SARS-CoV-2-RdRp. The above in silico investigations concluded that stachyflin is the most 'lead' candidate with the most potential against SARS-CoV-2. Previously, stachyflin also exhibited potential activity against HSV-1 and CoV-A59 within IC50, 0.16-0.82 µM. Therefore, some additional pharmacological studies are needed to develop 'stachyflin' as a drug against SARS-CoV-2.
Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links